Method of treating mantle cell lymphoma
AssigneeMayo Foundation for Medical Education and Research
InventorsThomas E. Witzig, Scott H. Kaufmann
Life of this patent
Estimating the term…
Abstract
This invention provides the use of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) in the treatment or inhibition of mantle cell lymphoma.
Claims13
A regimen for treating mantle cell lymphoma in a human patient, said regimen comprising delivering to the patient rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) as a single active agent in a monthly cycle of treatment, said monthly cycle comprising administering a first intravenous dosage of CCI-779 comprising about 175 mg to about 250 mg per week for at least one week in the cycle followed by a decreased intravenous dose of CCI-779 of about 25 mg to 75 mg for at least one week of the cycle.
A regimen for reducing tumor size in a relapsed mantle cell lymphoma human patient, said regimen comprising intravenously delivering to the patient a monthly cycle which comprises an intravenous dosage of about 175 to about 250 mg of CCI-779 per week as a single active agent followed by at least one weekly administration of a decreased intravenous dosage of about 75 mg per week.
Dependencies are inferred from the claim text.